Novavax Inc
NVAX-
Novavax soared 124% to $10.02 after the company announced a multi-billion-dollar deal with Sanofi to co-commercialize its COVID vaccine starting as early as 2025.
Sanofi agreed to pay Novavax an upfront licensing fee of $500 million and an additional fee of $700 million based on reaching certain milestones.
May 10, 2024
|
|
| |
|
| Trading Volume | 88,611 |
|
|
21.24 - 3.76 |
| Market Cap Full | $ 1.4B |
Quarterly +
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Q1 | 10.2% | -0.6% | -32.6% | -48.5% |
| Q2 | - | 175.3% | 7.2% | -30.2% |
| Q3 | - | -10.7% | -2.6% | -64.6% |
| Q4 | - | -11.3% | -32.3% | -43.5% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2025 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| -16.7 | 23.5 | -3.4 | -16.8 | 278.8 | -14.7 | -0.5 | -10.7 | - | - | - | - |
| 2023 | |||||||||||
| 6.1 | -15.1 | -25.2 | 10.7 | 5 | -7.7 | 24.9 | -13.8 | -9.5 | -8 | -17.4 | -12.7 |
| 2022 | |||||||||||
| -34.5 | -12.7 | -10 | -38.8 | 22.8 | -7.1 | 6 | -39.4 | -44.9 | 22.4 | -26 | -37.7 |
| 2021 | |||||||||||
| 98.1 | 4.7 | -21.6 | 30.7 | -37.7 | 43.8 | -14.1 | 30.8 | -12.3 | -28.9 | 40.2 | -31.4 |
| 2020 | |||||||||||
| 73.6 | 104.2 | -3.8 | 33.5 | 153.9 | 81 | 71.7 | -22.9 | -1.8 | -25.5 | 72.8 | -20.1 |
EPS
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Q1 | -3.4 | 2.6 | -3.1 | -0.6 |
| Q2 | 0.6 | -6.5 | -4.8 | -0.3 |
| Q3 | -1.3 | -2.2 | -4.3 | -3.2 |
| Q4 | 0 | -2.3 | -11.3 | -3.2 |
| A | -4.09 | -8.4 | -23.4 | -7.3 |